Count What Matters: Advanced Metrics to Value a Pharma Patent Portfolio Before the Generic Cliff
In the high-stakes world of pharmaceuticals, the countdown to the “generic cliff” can feel like a ticking time bomb for patent portfolios. As patent expirations loom, companies scramble to assess the true value of their assets—not just through traditio…
